InsiderClue
Stocks · Health care · Pharmaceutical Preparations

BIOHARVEST SCIENCES INC.

BHST Clue Score59
British Columbia, Canada Fiscal year ends December CIK 0001723464
$1.82 +12.35% Close, 13 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.82 +586.53% Close, 13 Oct 2026

Closing prices at the end of each trading day, from 8 Mar 2019. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2023Revenue12.7Operating income−10.0Net income−12.6Fiscal year 2024Revenue25.2 +98.8%Operating income−7.0Net income−12.9Fiscal year 2025Revenue34.5 +37.0%Operating income−5.6Net income−11.1
FY2023FY2024FY2025
Revenue 12.7 25.2 34.5
Growth +98.8% +37.0%
Operating income −10.0 −7.0 −5.6
Net income −12.6 −12.9 −11.1
Growth

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2023Gross margin44.5%Operating margin−78.6%Net margin−99.1%Free cash flow margin−78.9%Fiscal year 2024Gross margin55.4%Operating margin−27.7%Net margin−51.3%Free cash flow margin−37.8%Fiscal year 2025Gross margin59.3%Operating margin−16.2%Net margin−32.3%Free cash flow margin−27.8%
FY2023FY2024FY2025
Gross margin 44.5% 55.4% 59.3%
Operating margin −78.6% −27.7% −16.2%
Net margin −99.1% −51.3% −32.3%
Free cash flow margin −78.9% −37.8% −27.8%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow−8.5Capital expenditure−1.5Free cash flow−10.0Fiscal year 2024Operating cash flow−6.7Capital expenditure−2.8Free cash flow−9.5Fiscal year 2025Operating cash flow−7.2Capital expenditure−2.4Free cash flow−9.6
FY2023FY2024FY2025
Operating cash flow −8.5 −6.7 −7.2
Capital expenditure −1.5 −2.8 −2.4
Free cash flow −10.0 −9.5 −9.6
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash and securitiesTotal debt
Fiscal year 2023Cash and securities5.4Total debt0.0Net cash (debt)5.4Shareholders’ equity−14.9Fiscal year 2024Cash and securities2.4Total debt3.9Net cash (debt)−1.5Shareholders’ equity1.3Debt to equity2.94Fiscal year 2025Cash and securities23.0Total debt0.1Net cash (debt)22.9Shareholders’ equity25.4Debt to equity0.01
FY2023FY2024FY2025
Cash and securities 5.4 2.4 23.0
Total debt 0.0 3.9 0.1
Net cash (debt) 5.4 −1.5 22.9
Shareholders’ equity −14.9 1.3 25.4
Debt to equity n/a 2.94 0.01

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Balance sheet

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Assets
5.4 2.4 23.0
0.8 1.1 2.0
2.5 3.7 4.6
3.9 7.8 8.3
15.0 25.0 47.7
Growth +66.7% +90.7%
Liabilities
0.0 3.9 0.1
calc 0.0 3.9 0.1
Equity
−83.5 −96.4 −107.6
−14.9 1.3 25.4
Growth +1,813.4%
Per share and net cash
calc 5.4 −1.5 22.9
n/a 17.3 22.7
calc n/a 0.08 1.12

Lines marked calc are worked out here from filed figures; point at one for how.